About Neuroptika
Neuroptika is a company based in Cambridge (United States) founded in 2018 by Chiho Fukiage. Neuroptika has raised $3 million across 1 funding round from investors including KB Investment. Neuroptika offers products and services including NRO-1, NRO-CMK, NRO-VTN, and Undisclosed Therapy. Neuroptika operates in a competitive market with competitors including Annexon, Aldeyra, Nicox, Gyroscope and MeiraGTx, among others.
- Headquarter Cambridge, United States
- Founders Chiho Fukiage
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Neuroptika Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3 M (USD)
in 1 rounds
-
Latest Funding Round
$3 M (USD), Series A
Jan 15, 2019
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Neuroptika
Neuroptika offers a comprehensive portfolio of products and services, including NRO-1, NRO-CMK, NRO-VTN, and Undisclosed Therapy.
Regenerates corneal nerves for dry eye disease treatment
Protects retinal cells for glaucoma management
Inhibits drusen to treat dry age-related macular degeneration
Targets diabetic retinopathy and related eye conditions
Funding Insights of Neuroptika
Neuroptika has successfully raised a total of $3M through 1 strategic funding round. The most recent funding activity was a Series A round of $3 million completed in January 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Neuroptika
Neuroptika has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include KB Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund investing in early-stage tech startups
|
Locked | Locked | Locked |
Investor details for Neuroptika
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Neuroptika
Investment portfolio details for Neuroptika
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Neuroptika
Detailed financials for Neuroptika
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neuroptika Comparisons
Peer comparison for Neuroptika
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Neuroptika
Neuroptika operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Annexon, Aldeyra, Nicox, Gyroscope and MeiraGTx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| Locked | Locked | Locked |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
|
| Locked | Locked | Locked |
Mobile SDK developed for app engagement and monetization strategies.
|
|
| Locked | Locked | Locked |
Gene therapies for ocular and neurodegenerative diseases are developed.
|
|
| Locked | Locked | Locked |
Viral vector-based gene therapies for retinal diseases are developed.
|
Detailed competitors of Neuroptika
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neuroptika
Complete news archive for Neuroptika
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neuroptika
Neuroptika was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Neuroptika is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Hyunsuk Tim Min is the current CEO of Neuroptika.
Neuroptika is a funded company, having raised a total of $3M across 1 funding round to date.
Neuroptika was founded in 2018 and is based in Cambridge, United States. Operations focus on the biotechnology sector, specifically the discovery and development of regenerative therapies for ophthalmic conditions. The NRO-1 technology, a topically delivered nerve regenerative therapy, has completed a phase 1 clinical study and demonstrated neuron regeneration in nonclinical studies. Leadership includes co-founder Chiho Fukiage and CEO Hyunsuk Tim Min.
Neuroptika's top competitors include Annexon, Alimera Sciences and MeiraGTx.
Neuroptika offers NRO-1, NRO-CMK, NRO-VTN, and Undisclosed Therapy.
Neuroptika has 1 investor. Key investors include KB Investment.